CloudCheckr is an integral part of PTP’s PeakPlus cloud managed services platform. The CloudCheckr CMx platform provides single-pane visibility into cloud environments to help MSPs lower their customers’ costs, optimize and automate resources, and maintain rigorous security and compliance standards.
“CloudCheckr provides valuable insights and information to customers like Voyager Therapeutics,” said Eric Ransden, Director of Account Services and Partner at PTP. “CloudCheckr CMx finds opportunities for cost optimization and includes robust features for billing and security best practices that we can bring to our customers.”
As a cloud-centric organization, PTP differentiates itself from other IT partners that offer cloud as an add-on only. CloudCheckr allows them to further set themselves apart with business-critical tools that support their clients’ cloud journeys.
“We want to work with partners that are helping us provide value to customers like Voyager,” said Ransden. “CloudCheckr is a huge enabler to us to help deliver that value.”
The combined expertise of PTP and CloudCheckr enables Potier to focus on his role as a data scientist and support Voyager’s research staff instead of tracking costs manually. “CloudCheckr allows me to monitor AWS and know how much we spend directly, so I can focus my attention somewhere else,” Potier said.
Gary Derheim, Vice President of Managed Services at PTP, explained that PTP takes advantage of CloudCheckr’s API, so that they can pull critical metrics into the PTP portal. Looking at these comparative metrics, without divulging any sensitive data, can give their clients a new perspective on performance.
“We’re seeing continued improvement with functionality and the ability for our DevOps team to leverage the CloudCheckr API,” said Derheim. “We can connect it to our portal and begin to automate some of the work that we’re doing, which means that for a lower cost I can deliver more value back to customers like Voyager. That’s a win for us and I think a win for the customer.”
Cost optimization has been a major result for Voyager, said Derheim. “In one month, we saw a 25.4% cost reduction in terms of month A to month B spend,” he explained. “With an ever-changing and growing cloud environment, we continue to do things like put Reserved Instances in play based on the recommendations from CloudCheckr.”
Derheim said he also identified five key areas to improve Voyager’s security and compliance governance based on recommendations from CloudCheckr. Tong and Potier were then able to make changes to address them and improve their security posture.
Voyager also has access to CloudCheckr, so that they have greater insight into their AWS resources. Tong said that he uses CloudCheckr once or twice a month, and PTP meets with him and Potier regularly to review the improvements that CloudCheckr suggests. With a lean team at Voyager, Tong explained that PTP and CloudCheckr make it easier to “see how secure and compliant we are and to see that we’re making progress.”
“What AWS, PTP, and CloudCheckr allow us to do is that we scale up what we do,” said Potier. “The needs of the life sciences industry are quite specific at times. In that case, having PTP translate and leverage the metrics from CloudCheckr and explain it to us is really important.”
The ability to scale will assist Voyager in its growth, which will require compliance with more rigorous industry regulations. Tong explained, “Knowing that PTP has that Life Sciences Competency and tools like CloudCheckr makes us feel comfortable that they understand the complexity, the urgency, and the detail that’s required at the beginning to build out the environment and help guide us so that there’s not a lot of re-work later as we move into that regulated and more audited use case.”
PTP and CloudCheckr have helped Voyager implement the right technology to scale their data analysis and continue their research into treatments for debilitating neurodegenerative conditions. The ability to scale is vital in Voyager’s mission to find answers.
“Voyager is working hard to deliver life-changing therapies for severe neurological diseases,” said Ransden. “They are working quickly to achieve results that will both change the industry and people’s lives.”